Chimeric antigen receptor t cell therapy
AssigneeKite Pharma, Inc.
InventorsAdrian Bot, Michael David Mattie
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric antigen receptor genetically modified T cell immunotherapy and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to a T cell immunotherapy based on the levels of attributes prior to and after administration of the immunotherapy to the patient.
Claims29
A method of increasing the efficacy and/or reducing the toxicity of immunotherapy (e.g., T or non-T cells, TCR, CAR), bi-specific T-cell engagers (BiTEs), and/or immune checkpoint blockade treatment in a subject in need thereof, comprising:
- (i) administering to the subject a JAK/STAT inhibitor and decreasing the subject's systemic inflammatory state;
- and/or
- (ii) administering to the subject a JAK/STAT inhibitor and reducing the activity of myeloid cells, MCP-1, IL-6, and/or activated T cells in the subject,
- prior to, during, and/or after immunotherapy (e.g., T or non-T cells, TCR, CAR), (BiTEs), and/or immune checkpoint blockade treatment, preferably, T cell immunotherapy.
(canceled)
A method of treating, preventing, delaying, reducing or attenuating the development or risk of a toxicity and/or for improving immunotherapy (e.g., T or non-T cells, TCR, CAR), bi-specific T-cell engagers (BiTEs), and/or immune checkpoint blockade treatment therapy efficacy in a subject in need thereof, comprising administering to the subject a JAK/STAT inhibitor before, after, and/or during immunotherapy (e.g., T or non-T cells, TCR, CAR), bi-specific T-cell engagers (BiTEs), and/or immune checkpoint blockade treatment.
(canceled)
(canceled)
(canceled)
(canceled)
A method of reducing cytokine signaling and the inflammatory state in a tumor treated by immunotherapy (e.g., T or non-T cells, TCR, CAR), bi-specific T-cell engagers (BiTEs), and/or immune checkpoint blockade treatment in a subject in need thereof, comprising administering to the subject a JAK/STAT inhibitor prior to, during, and/or after immunotherapy (e.g., T or non-T cells, TCR, CAR), bi-specific T-cell engagers (BiTEs), and/or immune checkpoint blockade treatment administration.
(canceled)
(canceled)
(canceled)
-33. (canceled)
Dependencies are inferred from the claim text.